Do initial hematologic indices predict the severity of COVID-19 patients?

Ali ASAN1,*, Yasemin ÜSTÜNDAĞ2, Nizameddin KOCA3, Abdullah ŞİMŞEK4, Halil Erkan SAYAN5, Hülya PARILDAR6, Burcu Dalyan CİLO7, Kağan HUYSAL2

1Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
2Department of Clinical Biochemistry, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
3Department of Internal Medicine, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
4Department of Pulmonary Diseases, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
5Department of Anesthesiology and Reanimation, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey
6Department of Family Medicine, University of Health Sciences, Tepecik Trainingand Research Hospital, İzmir, Turkey
7Department of Microbiology, University of Health Sciences, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

Background/aim: In this study, we aimed to evaluate the initial hematological findings analyzed on admission in confirmed COVID-19 patients who were transferred to the intensive care unit (ICU), to predict possible hematological indices.

Materials and methods: Initial neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), red cell distribution width to platelet ratio (RPR), mean platelet volume to platelet ratio, and lymphocyte multiplied by platelet count (LYM × PLT), of 695 patients with laboratory-confirmed COVID-19 were investigated and comparisons were made between the mild/moderate and severe groups.

Results: The proportion of COVID-19 cases admitted to the ICU was 3.9%. The median age of patients admitted to the ICU was significantly higher than those who were not; [68.5 (interquartile range (IQR); 21.5] years vs. 41.0 (IQR; 15.7) years; P < 0.001.

Severe cases had higher NLR (6.6 vs. 2.4; P < 0.001), and MLR (0.40 vs. 0.28; P = 0.004) and lower PLR (180.0 vs. 129.0; P < 0.001) compared to that of mild or moderate patients. Among all of the parameters, the ROC curve of NLR gave us the best ability to distinguish serious patients at an early stage (AUC = 0. 819, 95% confidence interval 0.729–0.910; P < 0.001).

Conclusion: These data showed that age, initial NLR, PLR, and LYM × PLT were associated with the severity of COVID-19 disease and patients’ need for the ICU. Therefore, initial hemogram parameters may be essential to predict the prognosis of COVID-19 patients.

Key words: Intensive care unit, COVID-19, neutrophils, leukocytes, platelets

1. Introduction

In December 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in Wuhan, China; and quickly spread around the World [1]. The World Health Organization named this infection COVID-19 and announced a pandemic1. In our country, the first PCR positive COVID-19 case was detected on March 11th, 20202.

The clinical spectrum of COVID-19 infection can vary from asymptomatic to severe disease (e.g., acute respiratory distress syndrome [ARDS], acute cardiac injury, and acute kidney injury) [1,2]. Up to 32% of all positive patients require intensive care unit (ICU) admission, and death can occur [2,3]. Therefore, early identification of patients with severe disease risk and those that may potentially develop a life-threatening condition is important.

Increasing evidence supports the role of a dysfunctional immune response to the airway damage and the progression of various viral pneumonia, including COVID-19 [4,5]. Hematological indices, such as neutrophil to lymphocyte

1 WHO (2020). WHO: Novel coronavirus (2019-nCoV) situation report-51 2020 [online]. Website https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?2 [accessed 10 May 2020].
2 Republic of Turkey Ministry of Health (2020). COVID-19 Information Page [online]. Website https://covid19.saglik.gov.tr/ [accessed 14 May 2020].
* Correspondence: yaseminbudak2000@yahoo.com
ratio (NLR), platelet to lymphocyte (PLR) ratio, monocyte to lymphocyte ratio (MLR), lymphocyte count multiplied by platelet count (LYM × PLT), red cell distribution width to platelet ratio (RPR), are indicators of the systemic inflammatory response and have been extensively investigated in various diseases [6–9]. Abnormal blood count results were detected in patients with COVID-19 [4,10–12], which are considered to be potential predictors of the outcomes [13,14].

In this study, we aimed to identify hematological indices of confirmed COVID-19 patients that were analyzed on admission and their relationship with the disease severity, in order for them to be used in predicting the disease progression.

2. Materials and methods

The study was approved by the ethics committee of SBU Bursa Yüksek İhtisas Training and Research Hospital (No. 2020/05-02); a pandemic hospital with 1430 beds served as the setting for the present retrospective cohort study. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki.

Combined nasopharyngeal and oropharyngeal swabs were taken from 1100 patients who met the suspected case definitions for COVID-19. Real-time quantitative amplification of SARS CoV RNA was performed with SARS-CoV-2 (2019-nCoV) RT-qPCR Detection Kit (Bio-Speedy®, Bioeksen R&D Technologies, İstanbul, Turkey) with a thermal cycler device (CFX96TM Real-Time System, Bio-Rad Laboratories, Singapore) according to the manufacturer's instructions. Six-hundred and ninety-five confirmed SARS-CoV-2 patients admitted to our hospital between March 27th and April 30th, 2020, were included in the study. Individuals younger than 18 years old, those who required aggressive treatment within 24 h of admission, and those with an absence of initial complete blood count (CBC) test results were excluded from the study.

Twenty-seven patients who fulfilled one of the following criteria; dyspnea and respiratory distress; respiratory rate > 30/min, PaO2 / FiO2 <300; SPO2 <90 despite 5 L/min oxygen treatment, PaO2 <70, hypotension (systolic blood pressure <90 mmHg and/or more than 40 mmHg decrease and mean arterial pressure <65 mmHg), tachycardia >100/ min, acute kidney injury, development of acute organ dysfunction, patients with immunosuppression, acute bleeding diathesis, troponin increase, arrhythmia, lactate > 2 mmol, capillary return disorder, and cutis marmoratus were transferred to ICU.

The initial triage protocol of COVID-19 patients involves drawing blood samples upon admission. CBCs were analyzed within 1 h after venipuncture using an automatic blood counter (Mindray BC-5800; Mindray Bio-medical Electronics Co. Ltd., Shenzhen, China). Mean platelet volume divided by platelet count (MPV to PLT) and lymphocyte multiplied by platelet (LYM × PLT) were recorded. NLR, PLR, and MLR were calculated by dividing the number of neutrophils, platelet, and monocyte count by the lymphocyte count. RDW to platelet ratio (RPR) was calculated using the formula (RDW ×100 / PLT (10⁵ / L).

3. Statistical analysis

Statistical analysis was performed using SPSS (Statistical Package for Social Sciences) for Windows (SPSS Inc, Chicago, IL), and P values of <0.05 were considered significant. Descriptive statistics are presented as frequency distribution and percentage. The Kolmogorov–Smirnov test was used to identify the distribution of variables. Statistically significant differences between the variables were established using the MannWhitney U test. A binary logistic regression analysis was performed to determine the influence of age and all other significant factors.

4. Results

The proportion of COVID-19 cases admitted to ICU was 3.9%. Signs and symptoms of severe cases on admission included self-reported fever (52%), cough (44%), shortness of breath (52%), sore throat (19%), myalgia/arthritis (19%), fatigue (15%), chest pain/discomfort (11%), nasal symptoms (11%), headache (11%), nausea/vomiting (11%) and diarrhea (4%).

During the study period, the median age of patients who were transferred to ICU was significantly higher than those who were not transferred [68.5 (interquartile range (IQR); 21.5) years vs. 41.0 (IQR; 15.7) years; P <0.001, Table 1].

When comparing the initial hemoglobin concentration [12.9 (4.0) vs. 13.8 (2.3) g/dL; P < 0.001] and lymphocyte count [12.7% (12.6) vs. 26.6% (15.7)] both values were found to be lower than that of nonsevere cases (Table 1).

It is observed that severe cases had higher NLR (6.6 vs. 2.4; P < 0.001), and MLR (0.40 vs. 0.28; P = 0.004) and lower PLR (180.0 vs. 129.0; P < 0.001) compared to mild or moderate patients (Table 1). The ROC curve of NLR gave us the best prediction opportunity for distinguishing patients with severe disease from an earlier stage (AUC = 0.819, 95% confidence interval 0.729–0.910; P < 0.001, Table 2).

Potential risk factors, including age, NLR, PLR, LYM × PLT, and RDW were investigated using binary logistic regression analysis. Age was found to be the only significant (b = 0.070, SE = 0.015, P < 0.001) positive predictor for ICU requirement, with the OR 1.073 (95% CI, 1.042 to 1.104) (Table 3).
5. Discussion

On admission, the COVID-19 patients who needed to be taken to the ICU were older than those that did not require ICU intervention, as reported before [1,2]. In the ICU-patient group, the initial absolute neutrophil count was higher, and the lymphocyte count was lower among patients who were transferred to the ICU compared to mild cases who were not. This is in accordance with the previous publications that reported the increase in leukocyte count and a decrease in lymphocyte count as an indicator for clinical deterioration in COVID patients [16,17].

Neutrophils are the most important cellular defense line against infections, which first respond to viral invasion, and limit the viral replication and spread. However, neutrophils have also been reported to mediate deleterious effects on the host during viral infection [18]. The immune response to a viral infection is mainly based on lymphocytes. It has been assumed that a significant decrease in lymphocyte count may be due to increased lymphocyte consumption, destruction of lymphatic tissues, and cytokine-induced T-cell apoptosis in patients with COVID-19 [13,19]. Lymphopenia, as a sign of the severe disease, is not specific to COVID-19. It has also been seen in other viral causes of pneumonia, such as influenza [20,21].

Notably, we observed that COVID-19 patients who were transferred to the ICU had lower lymphocyte count

| Table 1. Initial laboratory findings of patients with COVID-19. |
|---------------------------------------------------------------|
| Group 1 (N = 668) | Group 2 (N = 27) | P value |
| Age, median (IQR) | 41.0 (15.7) | 69.0 (21.0) | <0.001 |
| Male/female (%) | 47.3/52.7 | 55.6/44.4 | 0.127 |
| WBC count, ×10^9/L | 6.2 (2.95) | 8.3 (5.5) | 0.008 |
| Haemoglobin, g/dL | 13.8 (2.3) | 12.9 (4.0) | 0.012 |
| Hct (%) | 40.8 (5.9) | 38.6 (10.3) | 0.017 |
| Platelet count, ×10^9/L | 217 (74) | 192 (90) | 0.081 |
| NEU (%) | 63.8 (16.7) | 82.7 (21.5) | <0.001 |
| LYM (%) | 26.5 (15.7) | 12.8 (12.6) | <0.001 |
| MONO (%) | 7.5 (4.0) | 5.8 (5.0) | 0.004 |
| EOS (%) | 0.7 (1.3) | 0.1 (0.3) | <0.001 |
| MCV, mm^3 | 85.7 (5.8) | 84.4 (9.0) | 0.321 |
| MCH, pg | 29.1 (2.5) | 28.2 (4.3) | 0.391 |
| MCHC (g/dL) | 33.8 (1.2) | 33.3 (1.3) | 0.003 |
| RDW, % | 13.1 (1.2) | 13.8 (3.1) | 0.007 |
| MPV, fL | 9.6 (1.3) | 9.7 (1.4) | 0.241 |
| CRP, mg/L | 6.2 (13) | 73 (123) | <0.001 |
| MPV to PLT | 0.044 (0.018) | 0.053 (0.028) | 0.049 |
| NLR | 2.4 (2.0) | 6.6 (7.8) | <0.001 |
| PLR | 129 (70) | 180 (156) | <0.001 |
| MLR | 0.28 (0.2) | 0.40 (0.3) | 0.004 |
| LYM × PLT | 346.5 (274.9) | 169.3 (212.7) | <0.001 |
| RPR | 0.062 (0.020) | 0.076 (0.028) | 0.001 |

The patients were divided into two groups: Group 1: Patients not requiring ICU admission; Group 2: ICU admission required. ICU = intensive care unit; IQR = interquartile range; RBC = red blood cell; WBC = white blood cell; Hct = hematocrit; NEU = neutrophil; LYM = lymphocyte; MONO = monocyte; EOS = eosinophil; BASO = basophil; MCV = mean corpuscular volume; MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular haemoglobin concentration, RDW = red cell distribution width; MPV = the mean platelet volume; NLR = neutrophil to lymphocyte ratio; MLR = monocyte to lymphocyte ratio; LYM × PLT = lymphocyte multiplied by platelet; RPR = red cell distribution width to platelet ratio; MPV to PLT = mean platelet volume to platelet count ratio. Data are median (IQR) or n (%).
and higher NLR and PLR. In consistency with our study, Yang et al. suggested NLR ≥3.3 as an indicator with clinical symptoms to change disease status from mild to severe disease [22]. NLR is reported to be used as an early indicator for the severe disease, similar to previous findings from a different patient population [22,23].

In the current study, the median PLR of severe COVID patients was higher compared to that of nonsevere cases. The PLR, which reflects both aggregation and inflammation control, is a better marker for the decision of patients for transfer to the ICU than platelet or lymphocyte count alone. Changes in platelet count and activity are closely related to various diseases [24]. It has been shown in several studies that low platelet count is directly related to the severity of the disease in COVID-19 patients [12,25]. Platelets not only contribute to hemostasis but also participate in the inflammation and host defense. Decreased platelet production and increased consumption due to diffuse alveolar damage are thought to cause thrombocytopenia in COVID-19 patients [26,27].

In accordance with previous studies, the hemoglobin level was found to be lower in COVID patients who needed to be taken to the ICU when compared to that of milder COVID patients [28,29]. RDW is a measure of the change in erythrocyte volume and has been reported to be a predictor of mortality in some conditions, including infections [30]. The higher RDW is associated to increased inflammation markers which have been tightly correlated with the critical disease [31,32].

Table 2. Diagnostic performances of initial hematologic indices for distinguishing admission to ICU.

| Parameter | AUC (95% CI) |
|-----------|-------------|
| NLR       | 0.819 (0.729–0.910) |
| LYM × PLT | 0.786 (0.706–0.865) |
| PLR       | 0.746 (0.629–0.862) |
| RPR       | 0.686 (0.584–0.788) |
| MLR       | 0.663 (0.560–0.765) |
| MPV to PLT| 0.612 (0.492–0.732) |

AUC (95% CI) = area under the receiver operating characteristic curve (95% confidence interval); NLR = neutrophil to lymphocyte ratio; LYM = lymphocyte; PLT = platelet; MPV = mean platelet volume; PLR = platelet to lymphocyte ratio; RPR = red cell distribution width to platelet count; MLR = monocyte to lymphocyte ratio; MPV to PLT = mean platelet volume to platelet count ratio.

Table 3. Binary logistic regression analysis predicting the likelihood of admission to the ICU.

| Variable   | B    | S.E.  | OR with 95% CI      | P value |
|------------|------|-------|---------------------|---------|
| Age        | 0.070| 0.015 | 1.073 (1.042–1.104) | <0.001  |
| Sex        | –0.178| 0.479 | 0.837 (0.327–2.141) | 0.711   |
| NLR        | 0.106| 0.073 | 1.112 (0.964–1.281) | 0.145   |
| LYM × PLT  | –0.003| 0.002 | 0.997 (0.994–1.001) | 0.209   |
| PLR        | 0.005| 0.003 | 1.005 (0.999–1.011) | 0.086   |
| RPR        | 2.620| 12.244| 13.738 (0.00–36400) | 0.831   |
| MLR        | 0.340| 0.967 | 1.405 (0.211–9339)  | 0.725   |
| MPV to PLT | 4.471| 12.143| 87.422 (0.00–189700) | 0.713   |

OR = odds ratio; CI = confidence interval; NLR = neutrophil to lymphocyte ratio; LYM = lymphocyte; PLT = platelet; MPV = mean platelet volume; PLR = platelet to lymphocyte ratio; RPR = red cell distribution width to platelet; MLR = monocyte to lymphocyte ratio; MPV to PLT = mean platelet volume to platelet count ratio.
6. Conclusion
According to the results of this study, the variables, including the age of the patients, NLR, PLR, and LYM × PLT, are related to the severity of COVID-19 disease and may contribute to decision making for transferring patients to the ICU on admission. Therefore, initial CBC parameters should be monitored for predicting the prognosis of COVID-19 patients.

Limitations: This study was a retrospective, single-center study. Prospective and multicenter clinical studies might be required to avoid a certain degree of deviation and to support the findings.

Acknowledgement/Disclaimers/Conflict of interest
No financial support was received. The authors declare that they have no conflict of interests.

Informed consent
SBU Bursa Yüksek İhtisas Etkik Kurul 2011-KAEK-25 2020/05-02.

References
1. Wang D, Hu B, Hu C, Zhu F, Liu X et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA: The Journal of the American Medical Association 2020; 323(11): 1061-1069. doi: 10.1001/jama.2020.1585
2. Huang C, Wang Y, Li X, Ren N, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
3. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response. JAMA: The Journal of the American Medical Association 2020. doi:10.1001/ jama.2020.4031
4. Qin C, Zhou L, Hu Z, Zhang S, Yang S et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2020; 71 (15): 762-768. doi: 10.1093/cid/ciaa248
5. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. The Journal of Infection 2020; 80 (6): 607-613. doi: 10.1016/j.jinf.2020.03.037
6. Cai J, Wang K, Han T, Jiang H. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure. Medicine (Baltimore) 2018; 97 (46): e13324. doi: 10.1097/MD.00000000000013324
7. Russell CD, Parajuli A, Gale HJ, Bulteel NS, Schuetz P et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis. The Journal of Infection 2019;78 (5): 339-348. doi: 10.1016/j. jinf.2019.02.006
8. Liu Z, Li X, Zhang M, Huang X, Bai J et al. The role of mean platelet volume/platelet count ratio and neutrophil to lymphocyte ratio on the risk of febrile seizure. Scientific Reports 2018; 8: 15123. doi: 10.1038/s41598-018-33373-3
9. Fei Y, Zhang H, Zhang C. The application of lymphocyte*platelet and mean platelet volume/platelet ratio in influenza A infection in children. Journal of Clinical Laboratory Analysis 2019; 33 (9): e22995. doi: 10.1002/jcla.22995
10. Fu L, Wang B, Yuan T, Chen X, Ao Y et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. The Journal of Infection 2020; 80 (6): 656-665. doi: 10.1016/j.jinf.2020.03.041
11. Sun S, Cai X, Wang H, He G, Lin Y et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clinica Chimica Acta: International Journal of Clinical Chemistry 2020; 507: 174-180. doi: 10.1016/j. cca.2020.04.024
12. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clinica Chimica Acta: International Journal of Clinical Chemistry 2020; 506: 145-148. doi: 10.1016/j. cca.2020.03.022
13. Tan L, Wang Q, Zhang D, Ding J, Huang Q et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduction and Targeted Therapy 2020; 5: 33. doi: 10.1038/s41392-020-0148-4
14. Terpos, E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN et al. Hematological findings and complications of COVID-19. American Journal of Hematology 2020; 95(7): 834-847. doi: 10.1002/ajh.25829
15. Cetinkaya E, Senol K, Saylam B, Tez M. Red cell distribution width to platelet ratio: new and promising prognostic marker in acute pancreatitis. World Journal of Gastroenterology 2014; 20 (39): 14450-14454. doi: 10.3748/wjg.v20.i39.14450
16. Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerging Infectious Diseases 2020; 26 (8): 1839-1841. doi: 10.3201/eid2608.201160
17. Shang W, Dong J, Ren Y, Tian M, Li W et al. The value of clinical parameters in predicting the severity of COVID-19. Journal of Medical Virology 2020. doi: 10.1002/jmv.26031
18. Naumenko V, Turk M, Jenne CN, Kim SJ. Neutrophils in viral infection. Cell and Tissue Research 2018; 371 (3): 505-516. doi: 10.1007/s00441-017-2763-0
19. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology 2017; 3: 529-539. doi: 10.1007/s00281-017-0629-x
20. Bellelli V, d’Ettorre G, Celani L, Borrazzo C, Ceccarelli G et al. Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. Critical Care 2019; 23: 330. doi: 10.1186/s13054-019-2608-1

21. Gu J, Gong E, Zhang B, Zheng J, Gao Z et al. Multiple organ infection and the pathogenesis of SARS. The Journal of Experimental Medicine 2005; 202: 415-424. doi: 10.1084/jem.20050828

22. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International Immunopharmacology 2020; 84: 106504. doi: 10.1016/j.intimp.2020.106504

23. Ding X, Yu Y, Lu B, Huo J, Chen M et al. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019. Clinical Chemistry and Laboratory Medicine 2020. doi: 10.1515/cclm-2020-0411

24. Zarychanski R, Houston DS. Assessing thrombocytopenia in the intensive care unit: the past, present, and future. Hematology, American Society of Hematology Education Program 2017; 2017: 660-666. doi: 10.1182/asheducation-2017.1.660

25. Liu Y, Sun W, Guo Y, Chen L, Zhang L et al. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets 2020; 31 (4): 490-496. doi: 10.1080/09537104.2020.1754383

26. Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology 2005; 10: 101-105. doi: 10.1080/102453304000026170

27. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ et al. Clinical characteristics of Coronavirus disease 2019 in China. The New England Journal of Medicine 2020; 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032

28. Yang X, Yu Y, Xu J, Shu H, Xia J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine 2020; 8 (5): 475-481. doi: 10.1016/S2213-2600(20)30079-5

29. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA: The Journal of the American Medical Association 2020; 323 (15): 1488-1494. doi: 10.1001/jama.2020.3204

30. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Archives of Pathology and Laboratory Medicine 2009; 133 (4): 628-632. doi: 10.1043/1543-2165-133.4.628

31. He Y, Liu C, Zeng Z, Ye W, Lin J et al. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. ClinicalRheumatology 2018; 37 (1): 161-167. doi: 10.1007/s10067-017-3871-7

32. Bazick HS, Chang D, Mahadevappa K, Gibbons FK, Christopher KB. Red cell distribution width and all-cause mortality in critically ill patients. Critical Care Medicine 2011; 39 (8): 1913-1921. doi: 10.1097/CCM.0b013e31821b85c6